结核病治疗领域近期进展
本文为叙述性综述,总结药物敏感结核病和耐药结核病的治疗现状、近期临床试验结果及在研试验。新化合物(贝达喹啉、德拉马尼、普托马尼)及利福霉素类剂量优化带来缩短疗程的希望;国际与WHO指南已据此多次更新。未来研究应个体化方案、保护近期突破并防止耐药选择。
要点
- 贝达喹啉、德拉马尼、普托马尼等新化合物进入市场,III期试验显示缩短药物敏感及耐药结核病疗程的潜力。
- 利福霉素类及老药再定位的剂量优化带来开发更安全有效方案的希望。
- 国际与WHO临床指南近年在上述进展基础上多次更新。
核心结论
- 结核病仍是全球健康挑战和主要死因之一,近十年治疗格局已发生重大变化。
- 未来研究应个体化方案,并通过预防和识别耐药选择、提供广泛可负担且以患者为中心的新治疗选择来保护近期突破。
研究设计与样本
- 叙述性综述,在PubMed和MEDLINE进行非系统性文献检索,聚焦结核病治疗。
- 在研临床试验依据作者知识并参考clinicaltrials.gov及其他公开网站(www.resisttb.org/clinical-trials-progress-report、www.newtbdrugs.org/pipeline/trials)列出。
主要发现
- 贝达喹啉、德拉马尼和普托马尼进入市场,III期试验显示缩短药物敏感结核病(Study 31/A5349、TRUNCATE-TB、SHINE)和耐药结核病(STREAM、NiX-TB、ZeNix、TB-PRACTECAL)疗程的潜力。
- 利福霉素类及老药再定位的剂量优化带来进一步开发安全有效方案的希望。
- 国际与WHO临床指南近年在上述进展基础上多次更新。
- 综述还讨论了宿主导向治疗及药代动力学和药物基因组学进展,并概述在研治疗性临床试验的不同路径与目标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文为非系统性叙述性综述。
- 在研临床试验列表依据作者知识并参考公开网站,非系统检索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) is a global health challenge and one of the leading causes of death worldwide. In the last decade, the TB treatment landscape has dramatically changed. After long years of stagnation, new compounds entered the market (bedaquiline, delamanid, and pretomanid) and phase III clinical trials have shown promising results towards shortening duration of treatment for both drug-susceptible (Study 31/A5349, TRUNCATE-TB, and SHINE) and drug-resistant TB (STREAM, NiX-TB, ZeNix, and TB-PRACTECAL). Dose optimization of rifamycins and repurposed drugs has also brought hopes of further development of safe and effective regimens. Consequently, international and WHO clinical guidelines have been updated multiple times in the last years to keep pace with these advances. OBJECTIVES: This narrative review aims to summarize the state-of-the-art on treatment of drug-susceptible and drug-resistant TB, as well as recent trial results and an overview of ongoing clinical trials. SOURCES: A non-systematic literature review was conducted in PubMed and MEDLINE, focusing on the treatment of TB. Ongoing clinical trials were listed according to the authors' knowledge and completed consulting clinicaltrials.gov and other publicly available websites (www.resisttb.org/clinical-trials-progress-report, www.newtbdrugs.org/pipeline/trials). CONTENT: This review summarizes the recent, major changes in the landscape for drug-susceptible and drug-resistant treatment, with a specific focus on their potential impact on patient outcomes and programmatic TB management. Moreover, insights in host-directed therapies, and advances in pharmacokinetics and pharmacogenomics are discussed. A thorough outline of ongoing therapeutic clinical trials is presented, highlighting different approaches and goals in current TB clinical research. IMPLICATIONS: Future research should be directed to individualize regimens and protect these recent breakthroughs by preventing and identifying the selection of drug resistance and providing widespread, affordable, patient-centred access to new treatment options for all people affected by TB.
引用
- Motta I, Boeree M, Chesov D, et al. Recent advances in the treatment of tuberculosis. Clin Microbiol Infect. 2023. PMID: 37482332. doi:10.1016/j.cmi.2023.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。